JP2024501771A5 - - Google Patents

Info

Publication number
JP2024501771A5
JP2024501771A5 JP2023540927A JP2023540927A JP2024501771A5 JP 2024501771 A5 JP2024501771 A5 JP 2024501771A5 JP 2023540927 A JP2023540927 A JP 2023540927A JP 2023540927 A JP2023540927 A JP 2023540927A JP 2024501771 A5 JP2024501771 A5 JP 2024501771A5
Authority
JP
Japan
Prior art keywords
seq
substitution
amino acid
acid sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011504 external-priority patent/WO2022150521A1/en
Publication of JP2024501771A publication Critical patent/JP2024501771A/ja
Publication of JP2024501771A5 publication Critical patent/JP2024501771A5/ja
Pending legal-status Critical Current

Links

JP2023540927A 2021-01-06 2022-01-06 抗pd-l1抗体及びその融合タンパク質 Pending JP2024501771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134412P 2021-01-06 2021-01-06
US63/134,412 2021-01-06
PCT/US2022/011504 WO2022150521A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Publications (2)

Publication Number Publication Date
JP2024501771A JP2024501771A (ja) 2024-01-15
JP2024501771A5 true JP2024501771A5 (cg-RX-API-DMAC7.html) 2025-01-09

Family

ID=82357548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540927A Pending JP2024501771A (ja) 2021-01-06 2022-01-06 抗pd-l1抗体及びその融合タンパク質

Country Status (10)

Country Link
US (1) US20240067729A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274614A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024501771A (cg-RX-API-DMAC7.html)
KR (1) KR20230131236A (cg-RX-API-DMAC7.html)
CN (1) CN116829188A (cg-RX-API-DMAC7.html)
AU (1) AU2022206264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173557A1 (cg-RX-API-DMAC7.html)
IL (1) IL304190A (cg-RX-API-DMAC7.html)
MX (1) MX2023008028A (cg-RX-API-DMAC7.html)
WO (1) WO2022150521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
KR20230138473A (ko) * 2021-01-06 2023-10-05 팔레온 파마슈티칼스 인크. 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
EP4744681A1 (en) 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
KR20150131208A (ko) * 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3277320A4 (en) * 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
JP7462560B2 (ja) * 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111606995B (zh) * 2019-06-04 2021-02-12 优睿赛思(武汉)生物科技有限公司 抗人pd-l1单克隆抗体及其应用
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途

Similar Documents

Publication Publication Date Title
JP2020186248A5 (cg-RX-API-DMAC7.html)
JP2021508449A5 (cg-RX-API-DMAC7.html)
KR102917630B1 (ko) 인간 Tim-3에 대한 모노클로날 항체
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2022538894A5 (cg-RX-API-DMAC7.html)
JP2019506140A5 (cg-RX-API-DMAC7.html)
JP2019504617A5 (cg-RX-API-DMAC7.html)
CN109476741A (zh) 与cd38和pd-l1结合的分子
TW202233694A (zh) 雙特異性抗體
JP2023532021A5 (cg-RX-API-DMAC7.html)
JP2023508366A (ja) 二重特異性fcyriii×cd30抗体構築体の製造方法
WO2022057875A1 (zh) 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
KR20250028265A (ko) 항체 및 이의 용도
AU2022333089A1 (en) Bispecific tetravalent antibody targeting egfr and her3
JP2024501767A5 (cg-RX-API-DMAC7.html)
CN114786720A (zh) TriAx抗体的组合物及其制备和使用方法
JP2024542944A (ja) 抗メソテリンナノボディおよびその使用
JP2024501770A5 (cg-RX-API-DMAC7.html)
CN113461820B (zh) 抗cd3人源化抗体
EP3538552B1 (en) Fab molecules with a rodent hinge region and a non-rodent ch1 region
JP2023550191A (ja) Dr4および/またはdr5を標的とするポリペプチドならびに関連する組成物および方法
KR20250027598A (ko) Klrb1 결합제 및 이의 사용 방법
JP2024522092A5 (cg-RX-API-DMAC7.html)
JP2024515301A5 (cg-RX-API-DMAC7.html)
JP2024500945A5 (cg-RX-API-DMAC7.html)